Development of a novel cancer vaccine utilizing liposomes modified with complement activation polymer

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K18921
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Medical pharmacy
• Research Institution: The University of Tokushima
• Principal Investigator: SHIMIZU Taro 徳島大学, 大学院医歯薬学研究部(薬学系), 特任助教 (30749388)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: ワクチン / 抗原送達 / 補体 / リポソーム / 辺縁帯B細胞

Outline of Final Research Achievements

In this study, we tried to develop a novel type antigen delivery system. We focused on polymer-conjugated liposome that can activate complement system in order to deliver antigen to splenic marginal zone B cells. Widely-used conjugation polymer is polyethylene glycol (PEG) with methoxy terminal group (methoxy PEG). We found that hydroxyl PEG-conjugated liposomes spontaneously activated complement system and were selectively delivered to marginal zone B cells. Encapsulation of antigen and adjuvant into hydroxyl PEG-conjugated liposomes enhanced antigen-specific immune response. These results indicate that hydroxyl PEG-conjugated liposomes, which enable antigen delivery to marginal zone B cells, are novel antigen delivery system.

Free Research Field

薬剤学